GPT-Rosalind: OpenAI's Bold Bet That AI Can Crack Drug Discovery
A new drug takes 10 to 15 years and roughly $2.6 billion to go from lab bench to pharmacy shelf. Most candidates fail. The process is brutal, expensive, and maddeningly slow — especially if you’re one of the millions of people waiting for a treatment that doesn’t exist yet. On April 16, 2026, OpenAI decided it wanted to fix that. The company launched GPT-Rosalind, its first AI model built specifically for life sciences research — and in doing so fired a shot directly at Google DeepMind’s long-standing dominance in AI-powered biology. Named after Rosalind Franklin, the scientist whose X-ray crystallography work was essential to discovering DNA’s double helix, this isn’t just another ChatGPT update. It’s OpenAI’s declaration that the future of drug discovery runs through AI. ...